Human serum-free mixed lymphocytes response: the stereospecific effect of insulin and its potentiation by transferrin.
- 1 April 1982
- journal article
- research article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 128 (4), 1555-1559
- https://doi.org/10.4049/jimmunol.128.4.1555
Abstract
We have established a serum-free human mixed lymphocyte response (MLR). Proliferative unidirectional responses are discerned using peripheral blood leukocytes obtained from unrelated individuals and family members mismatched for HLA while MLR conducted between HLA identical siblings are negative. Resting lymphocytes lack insulin and transferrin receptors; activated lymphocytes are known to express insulin and transferrin receptors. Interestingly, physiologic concentrations of insulin and transferrin synergistically potentiate DNA synthesis in serum-free allogeneic cultures. To verify that the insulin effect was due to a stereospecific interaction between insulin and classical, high-affinity insulin receptors, insulin and a series of insulin-like peptides were compared in their ability to bind to alloactivated T cells and amplify the MLR. The results demonstrate the stereospecificity of the insulin effect in the MLR and underscore the importance of lymphocytic insulin receptors in the process of lymphocyte activation.This publication has 5 references indexed in Scilit:
- Cell-surface immunoglobulin and insulin receptor expression in an EBV-negative lymphoma cell line and its EBV-converted sublines.The Journal of Immunology, 1981
- The role of insulin in the response of murine T lymphocytes to mitogenic stimulation in vitro.The Journal of Immunology, 1980
- Transferrin can replace serum for in vitro growth of mitogen‐stimulated T lymphocytesEuropean Journal of Immunology, 1979
- Complete replacement of serum by albumin, transferrin, and soybean lipid in cultures of lipopolysaccharide-reactive B lymphocytes.The Journal of Experimental Medicine, 1978
- The chromosomal order of genes controlling the major histocompatibility complex, properdin factor B, and deficiency of the second component of complement.Journal of Clinical Investigation, 1976